Paula Green Sells 1,347 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green sold 1,347 shares of the stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $48.00, for a total transaction of $64,656.00. Following the sale, the senior vice president now owns 114,147 shares in the company, valued at $5,479,056. This represents a 1.17 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Paula Green also recently made the following trade(s):

• On Wednesday, November 6th, Paula Green sold 5,519 shares of Twist Bioscience stock. The shares were sold at an average price of $44.60, for a total value of $246,147.40.
• On Monday, November 4th, Paula Green sold 1,057 shares of Twist Bioscience stock. The stock was sold at an average price of $41.56, for a total value of $43,928.92.
• On Wednesday, October 2nd, Paula Green sold 3,310 shares of Twist Bioscience stock. The shares were sold at an average price of $43.21, for a total value of $143,025.10.
• On Friday, September 20th, Paula Green sold 297 shares of Twist Bioscience stock. The stock was sold at an average price of $46.94, for a total transaction of $13,941.18.

Twist Bioscience Price Performance

TWST stock opened at $38.96 on Friday. Twist Bioscience Co. has a 1-year low of $18.80 and a 1-year high of $60.90. The stock has a 50-day moving average price of $43.90 and a 200-day moving average price of $45.88.

Institutional Investors Weigh In On Twist Bioscience

Hedge funds have recently added to or reduced their stakes in the business. SageView Advisory Group LLC bought a new stake in shares of Twist Bioscience in the 1st quarter valued at $1,144,000. Susquehanna Fundamental Investments LLC bought a new stake in Twist Bioscience in the 1st quarter valued at about $300,000. Sei Investments Co. raised its stake in Twist Bioscience by 32.7% during the 1st quarter. Sei Investments Co. now owns 223,555 shares of the company’s stock worth $7,670,000 after buying an additional 55,124 shares during the period. Silvercrest Asset Management Group LLC boosted its holdings in Twist Bioscience by 38.6% in the first quarter. Silvercrest Asset Management Group LLC now owns 134,215 shares of the company’s stock worth $4,605,000 after acquiring an additional 37,376 shares in the last quarter. Finally, Principal Financial Group Inc. increased its holdings in shares of Twist Bioscience by 210.2% during the second quarter. Principal Financial Group Inc. now owns 122,911 shares of the company’s stock valued at $6,057,000 after acquiring an additional 83,287 shares in the last quarter.

Analysts Set New Price Targets

Several research firms have recently weighed in on TWST. Leerink Partners boosted their price target on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a report on Thursday, October 17th. JPMorgan Chase & Co. raised their price target on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research note on Monday, August 5th. Robert W. Baird boosted their price objective on shares of Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a research note on Monday, August 5th. Evercore ISI raised their target price on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Finally, Barclays reduced their price target on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 5th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $51.22.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.